Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

David F L Liew; Sarah L Mackie; Alice Tison; Sebastian E Sattui; Max Yates; Russell R C Buchanan; Claire E Owen

doi:10.1016/j.rdc.2024.02.001

Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

Rheum Dis Clin North Am. 2024 May;50(2):255-267. doi: 10.1016/j.rdc.2024.02.001.

Authors

David F L Liew¹, Sarah L Mackie², Alice Tison³, Sebastian E Sattui⁴, Max Yates⁵, Russell R C Buchanan⁶, Claire E Owen⁶

Affiliations

¹ Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia. Electronic address: david.liew@austin.org.au.
² Division of Rheumatic and Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Worsley Building, Leeds, West Yorkshire LS2 9NL, England.
³ LBAI UMR1227, Univ Brest, Inserm, Brest, France; Department of Rheumatology, CHU Brest, France Boulevard TANGUY PRIGENT, Brest, Brittany 29609, France.
⁴ Division of Rheumatology and Clinical Immunology, University of Pittsburgh, BST S723, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
⁵ Norwich Medical School, University of East Anglia, Norwich, UK; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK.
⁶ Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia.

PMID: 38670724
DOI: 10.1016/j.rdc.2024.02.001

Abstract

Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.

Keywords: Disease model; Immune-related adverse event; Mimics; PD-1 agonist; PD-1 inhibitor; Paraneoplastic; Peresolimab; Polymyalgia rheumatica.

Publication types

Review

MeSH terms

Humans
Immune Checkpoint Inhibitors* / adverse effects
Polymyalgia Rheumatica* / chemically induced
Polymyalgia Rheumatica* / drug therapy

Substances

Immune Checkpoint Inhibitors